Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia.
Bladder outlet obstruction in men with benign prostatic hyperplasia is decreased following administration of prazosin, a selective alpha1 adrenergic antagonist. Prazosin presumably binds and antagonizes alpha1 adrenergic receptors on the smooth muscle cells of the prostatic adenoma. This study represents the first identification and characterization of alpha1 adrenergic receptors in the prostate using radioligand receptor binding methods. The binding of [3H] prazosin in homogenates obtained from human prostatic adenomas was saturable and a single high affinity prazosin binding site was identified (Kd = 0.29 +/- 0.09 nM). The alpha1 adrenergic receptor concentration in these homogenates ranged between 0.28 to 2.05 fmol./ mg. wet wt. prostate. The equilibrium dissociation constant and density of prazosin binding sites were similar in different regions of an enucleated prostate suggesting homogeneity of receptor density and receptor binding sites within an adenoma. The receptor density was not directly proportional to the weight of the surgically removed adenoma. The pharmacology of the prazosin binding sites was characterized by competitive binding experiments using [3H] prazosin and several unlabelled adrenergic analogs. The IC50's determined from competitive binding experiments using [3H] prazosin and alpha-methylnorepinephrine, rauwolscine and corynanthine were characteristic of alpha1 adrenergic receptor binding.
D001665:Binding Sites; D001667:Binding, Competitive; D006801:Humans; D008297:Male; D011224:Prazosin / Q000378:metabolism*; D011467:Prostate / Q000294:innervation / Q000378:metabolism*; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D011799:Quinazolines / Q000378:metabolism*; D011869:Radioligand Assay; D011942:Receptors, Adrenergic, alpha / Q000032:analysis* / Q000378:metabolism; D014316:Tritium
D011799:Quinazolines; D011942:Receptors, Adrenergic, alpha; D014316:Tritium; D011224:Prazosin